Trials / Active Not Recruiting
Active Not RecruitingNCT06633536
Real-life Treatment Outcomes of Ravulizumab in PNH
Real-life Treatment Outcomes of Ravulizumab in Polish Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH). Prospective and Retrospective, Multicenter, Non-interventional Study.
- Status
- Active Not Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 64 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The PNH-RECORD study, a Polish multicenter observational (non-interventional), open-label, retrospective with prospective follow-up.
Detailed description
PNH-RECORD study aims to aims to collect data on the patients' characteristics and clinical outcomes of ravulizumab administered in the scope of routine clinical practice in PNH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ravulizumab | open-label arm with ravulizumab administrated within the scope of routine clinical practice |
Timeline
- Start date
- 2025-02-06
- Primary completion
- 2028-08-01
- Completion
- 2028-08-01
- First posted
- 2024-10-09
- Last updated
- 2026-04-01
Locations
11 sites across 1 country: Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06633536. Inclusion in this directory is not an endorsement.